Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
- 1 August 2002
- Vol. 60 (2) , 4-11
- https://doi.org/10.1016/s0090-4295(02)01686-2
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- The effects of sildenafil on human sperm function in healthy volunteersBritish Journal of Clinical Pharmacology, 2002
- The effects of steady‐state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteersBritish Journal of Clinical Pharmacology, 2002
- The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteersBritish Journal of Clinical Pharmacology, 2002
- A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunctionBritish Journal of Clinical Pharmacology, 2002
- The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafilBritish Journal of Clinical Pharmacology, 2002
- Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failureThe FASEB Journal, 2001
- Vertebrate PhotoreceptorsProgress in Retinal and Eye Research, 2001
- Pharmacokinetic interactions between sildenafil and saquinavir/ritonavirBritish Journal of Clinical Pharmacology, 2000
- Erectile DysfunctionNew England Journal of Medicine, 2000
- Clinical review of histamine2 receptor antagonistsArchives of internal medicine (1960), 1990